Who was studied?
Adults with HIV and abdominal fat accumulation received the historical 2 mg formulation daily or placebo. Most participants were men.
- Participants
- 412 adults
- Duration
- 26 weeks
- Funding
- Theratechnologies
What did the study find?
CT-measured visceral fat decreased 15.2% with tesamorelin and increased 5.0% with placebo at 26 weeks. This outcome is distinct from total body-weight loss.
What should you keep in mind?
The population and formulation matter. More tesamorelin participants withdrew because of an adverse event; this trial did not compare five-on/two-off schedules.
Why it matters
A daily, placebo-controlled trial gives the community a reference point, without showing that another formulation or schedule produces the same result.
Metabolic effects of a growth hormone-releasing factor in patients with HIV
Published 2007 · PMID 18057338 · DOI 10.1056/NEJMoa072375
Summary by Peptide Lit, checked against the original abstract on October 8, 2026. Read the complete paper for detailed methods and safety results. This page explains published research; it does not recommend a treatment or dose.